Építés alatt – nem éles oldal
Belépés
Befejeződött4. fázis

PREPARE-iVAC Trial

A legfontosabb adatok

Ki végzi
University Medical Center Groningen
Hol
Hollandia7 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Befejeződött
Fázis
4. fázis
Résztvevők
110 fő vett részt
Kezdés
2023. aug. 22.
Befejezés
2024. febr. 27.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • COVID-19 vaccination
A regiszteradat frissítve
2024. március 4.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 30 feltétel megnézéseKevesebb

Ki vehet részt

  • Age ≥ 18 years
  • ≥6 months after kidney transplantation
  • Maintenance immunosuppressive therapy consisting of either triple or dual therapy including MMF/MPA with a minimum daily dose of 1000 mg (MMF) or 720 mg (MPA) and a CNI
  • Eligible for the vaccinations as described by the instructions of the manufacturers of the vaccines (e.g. received 3 previous COVID-19 vaccinations as part of the primary COVID-19 immunisation)
  • Capable of understanding the purpose and risks of the study, fully informed and given written informed consent (signed informed consent form has been obtained)
  • Willing to adhere to the protocol and be available during the study period

Ki nem vehet részt

  • Previous CNI trough levels not sufficient according to the discretion of the treating physician
  • More than two previous kidney transplantations
  • Calculated level of panel reactive antibodies prior to last transplantation above 85%
  • Multi-organ transplant recipient
  • Administration of T-cell, B-cell, or plasma cell depleting antibodies during the last 6 months
  • Subjects with severe systemic infections, current or within the two weeks prior to randomisation
  • Herpes zoster vaccination with the live attenuated vaccine (Zostavax) or varicella vaccination (Provarivax) during the conduct of the study
  • Previous herpes zoster vaccination with the RZV
  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (e.g. anaphylaxis) to any component of the study intervention(s)
  • Active COVID-19 disease
  • Active malignancy, except non-melanoma skin cancer
  • Infection with Human Immunodeficiency Virus (HIV)
  • Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection
  • Subjects with severe restrictive or obstructive pulmonary disorders
  • Active varicella or herpes zoster disease
  • Subjects with white blood cell (WBC) count ≤ 2,000/mm3 or with platelet count ≤ 50,000/mm3 at last outpatient clinic visit
  • Evidence of DSAs
  • Signs of acute rejection during the preceding year
  • Contra-indications for use of everolimus according to the opinion of the treating physician
  • Inherited immune deficiency
  • Subjects with severe hypercholesterolemia or hypertriglyceridemia that cannot be controlled
  • Proteinuria > 1 gram/day at last outpatient clinic visit
  • Simultaneous participation in another interventional study that will likely influence the study outcomes
  • Subject who are actively trying to get pregnant or are pregnant; Additional exclusion criteria for Part 2:

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Objective: To investigate whether replacement of MMF/MPA by everolimus in kidney transplant recipients results in superior immunogenicity of COVID-19 vaccination as measured by neutralizing antibody titer against the Omicron XBB.1.5 strain.

A teljes eredeti leírásKevesebb

Trial design: Multicentre, open-label randomized controlled clinical trial, for a duration of at least 10 weeks with an optional extension to 18 weeks.

Trial population: Kidney transplant recipients, 18 years or older, who are at least 6 months after transplantation, with a functioning kidney transplant, using MMF/MPA in combination with at least one other immunosuppressant including a calcineurin inhibitor (CNI), with at least 3 previous COVID-19 vaccinations (=basic COVID-19 immunisation).

Interventions:

Patients will be randomized into one of two equally sized groups, with either continuation of their current immunosuppressive regimen including MMF/MPA or replacement of MMF/MPA by everolimus during at least six weeks before until four weeks after the last vaccination. Patients will receive a repeated COVID-19 vaccination with the monovalent Omicron XBB.1.5 vaccine, 28 days thereafter they can opt to also receive two herpes zoster vaccinations with the Recombinant Zoster Vaccine (RZV) with an interval between the first and second dose of 28 days.

Main trial endpoints:

The neutralizing antibody titer against the Omicron XBB.1.5. strain 28 days after monovalent Omicron XBB.1.5 COVID-19 vaccination in patients continuing MMF/MPA compared to patients who switched to everolimus.

Secondary trial endpoints:

* SARS-CoV-2 specific anti-S1 antibody level at 28 and 56 days after COVID-19 vaccination * Varicella zoster specific anti-gE antibody level 28 days after 1st and 2nd herpes zoster vaccination * SARS-CoV-2 specific T-cell response 28 days after COVID-19 vaccination * Varicella zoster specific T-cell response 28 days after 2nd herpes zoster vaccination * Safety in terms of incidence of acute rejection, kidney function decline, SAEs, AESIs and solicited local and systemic AEs after COVID-19 and herpes zoster vaccination

A vizsgálat 2 csoportja

  • Continue immunosuppressive therapy with MMF/MPAMár használt kezelés, összehasonlításként

    Kidney transplant recipients with maintenance therapy, receiving the monovalent Omicron XBB.1.5 COVID-19 mRNA vaccine (Comirnaty, I.M.). Optional to receive the Recombinant Zoster Vaccine (Shingrix, I.M.).

    Kezelés: COVID-19 vaccination

  • Replace immunosuppressive therapy with MMF/MPA by everolimusMár használt kezelés, összehasonlításként

    Kidney transplant recipients replacing MMF/MPA by everolimus for at least six weeks, receiving the monovalent Omicron XBB.1.5 COVID-19 mRNA vaccine (Comirnaty, I.M.). Optional to receive the Recombinant Zoster Vaccine (Shingrix, I.M.).

    Kezelés: COVID-19 vaccination

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
Prospective Randomized Trial of Everolimus Replacing MMF/MP Acid by the RECOVAC Consortium to Increase VACcine Response in Kidney Transplant Patients
A regiszteradat frissítve
2024. március 4.